Fortress Biotech (NASDAQ:FBIO – Get Free Report) announced its earnings results on Tuesday. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.32) by $0.59, Zacks reports. The business had revenue of $14.90 million for the quarter, compared to analysts’ expectations of $14.97 million.
Fortress Biotech Stock Up 5.0 %
Shares of NASDAQ FBIO traded up $0.09 during mid-day trading on Thursday, reaching $1.90. 412,933 shares of the company were exchanged, compared to its average volume of 311,407. The company has a quick ratio of 1.21, a current ratio of 1.33 and a debt-to-equity ratio of 38.42. The stock has a market cap of $38.78 million, a price-to-earnings ratio of -0.31 and a beta of 1.74. Fortress Biotech has a 1 year low of $1.24 and a 1 year high of $7.35. The firm has a 50-day moving average of $1.92 and a 200 day moving average of $1.89.
Insider Buying and Selling at Fortress Biotech
In other news, CEO Lindsay A. Md Rosenwald purchased 5,000 shares of the firm’s stock in a transaction on Monday, July 8th. The stock was acquired at an average cost of $7.35 per share, with a total value of $36,750.00. Following the completion of the transaction, the chief executive officer now owns 117,500 shares in the company, valued at approximately $863,625. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CEO Lindsay A. Md Rosenwald acquired 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The stock was purchased at an average cost of $7.35 per share, with a total value of $36,750.00. Following the transaction, the chief executive officer now directly owns 117,500 shares of the company’s stock, valued at approximately $863,625. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Lindsay A. Md Rosenwald purchased 20,000 shares of the firm’s stock in a transaction on Friday, June 28th. The stock was bought at an average cost of $1.64 per share, with a total value of $32,800.00. Following the acquisition, the chief executive officer now owns 2,893,905 shares of the company’s stock, valued at approximately $4,746,004.20. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 30,500 shares of company stock valued at $110,700. 33.40% of the stock is currently owned by insiders.
Analysts Set New Price Targets
Read Our Latest Stock Analysis on Fortress Biotech
About Fortress Biotech
Fortress Biotech, Inc, a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne.
Featured Articles
- Five stocks we like better than Fortress Biotech
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- Investing in the High PE Growth Stocks
- Jeff Brown’s Exegesis AI Stock Picks
- Overbought Stocks Explained: Should You Trade Them?
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.